1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shanghai Allist Pharmaceuticals Co. Ltd. Class A

Shanghai Allist Pharmaceuticals Co. Ltd. Class A

SSSE:688578
88.12
CNY
+3.62
(+4.28%)
6.12EPS
17.85P/E
49.14BMarket Cap
Oct 28Next Earn
Shanghai Allist Pharmaceuticals Co. Ltd. Class A
SSE:688578
(Shanghai Stock Exchange)

Recent

price

88.12

P/E

ratio

17.85

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.02
0.01
- -
- -
1.16
1.76
4.48
7.91
11.52
13.44
Revenue per Share
-0.09
-0.22
-1.1
-0.84
0.04
0.29
1.43
3.18
4.86
6.12
Basic EPS, GAAP
0.02
-0.3
-0.97
-0.77
-0.36
-0.12
1.35
2.88
4.74
- -
Free Cash Flow per Basic Share
0.01
0.01
0.09
- -
- -
- -
- -
0.65
0.8
- -
Dividend per Share
1.06
0.2
3.29
6.4
6.61
7.08
8.85
11.74
15.74
18.8
Book Value per Share
1.05
0.17
3.1
6.24
6.46
6.93
8.7
11.22
14.96
17.98
Tangible Book Value per Share
450
450
361
370
457
450
450
450
450
450
Basic Weighted Avg Shares
8
5
1
1
530
791
2,018
3,558
5,187
6,049
Sales/Revenue/Turnover
-629.33
-2,305.7
-62,431.01
-60,363.45
-9.34
5.85
28.24
43.21
47.84
52.21
Operating Margin (%)
6
6
10
12
23
25
39
39
43
- -
Depreciation Expense
-39
-97
-398
-311
18
131
644
1,430
2,189
2,755
Net Income, GAAP
- -
- -
- -
- -
- -
- -
1.84
11.66
13.98
14.36
Effective Tax Rate (%)
-503.87
-2,108.11
-63,123.32
-55,361.44
3.45
16.5
31.92
40.19
42.2
45.54
Profit Margin (%)
277
-81
842
2,561
2,219
2,032
2,518
3,580
3,365
4,130
Working Capital
- -
- -
- -
4
1
- -
- -
- -
2
2
LT Debt
381
71
1,184
2,878
2,973
3,187
3,982
5,283
7,083
8,462
Total Equity
- -
- -
- -
- -
0.74
- -
17.81
30.64
35.09
38.68
Return on Invested Capital (%)
- -
- -
- -
- -
0.64
- -
17.97
30.86
35.39
39.06
Return on Capital (%)
- -
-43.07
-63.33
-15.29
0.62
4.24
17.97
30.87
35.41
39.08
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
2
3
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
450
450
450
Market Capitalization
46,868
43,200
49,140

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,170
4,339
5,076
Cash, Cash Equivalents & STI
3,186
3,159
3,761
Accounts Receivable, Net
376
482
579
Inventories
72
65
87
Total Current Liabilities
806
826
945
Payables & Accruals
- -
- -
- -
ST Debt
2
2
3
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
20.44%
34.08%
Free Cash Flow
- -
-238.93%
64.88%
Net Income, GAAP
- -
215.39%
53.1%
Sales/Revenue/Turnover
- -
18,947.28%
45.8%
Total Cash Common Dividend
- -
- -
23.08%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
743
834
957
1,024
3,558
2025
1,098
1,275
- -
1,454
5,187
2026
1,584
1,736
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.68
0.78
0.9
0.82
3.18
2025
0.91
1.42
- -
1.27
4.86
2026
1.41
2.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.25
- -
0.65
2025
- -
- -
- -
- -
0.8
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS) develops, manufactures, and commercializes pharmaceutical products focused on anti-tumor therapies, cardiovascular treatments, and innovative small molecule drugs. The company offers core products including glecatinib (ALL-001), a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer; ALL-302, an ATR kinase inhibitor in clinical development for solid tumors; and a pipeline of preclinical candidates targeting DNA damage response pathways; alongside services in contract research, development, and manufacturing organization (CRDMO) capabilities for kinase inhibitors. Founded in 2016 and headquartered in Shanghai, China, Allist operates primarily in the People's Republic of China with expanding global partnerships for clinical trials and commercialization in Asia, Europe, and North America, targeting pharmaceutical companies, hospitals, and oncology research institutions. In the past two years, the company completed a significant strategic partnership with Hansoh Pharmaceutical Group Co., Ltd. in 2024 for co-development and commercialization of ALL-001 in Greater China, bolstering its market access; raised approximately CNY 1.5 billion in a follow-on funding round in early 2025 to advance Phase III trials for glecatinib and initiate new pipeline programs; and expanded its manufacturing facility in Shanghai's Zhangjiang Hi-Tech Park to support commercial-scale production of small molecule APIs, marking a key operational enhancement amid robust revenue growth from product approvals.